• Inhibrx Biosciences, Inc. reported second-quarter 2026 results, with net loss widening to US$36.65 million and basic loss per share from continuing operations at US$2.34, while first-half losses were broadly similar to the prior year.
• Alongside these figures, the company highlighted FDA acceptance of its biologics license application for ozekibart in conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027, and pointed to upcoming Phase 2 data for INBRX-106 in head and neck squamous cell carcinoma as key clinical milestones.
• We will now examine how the FDA’s acceptance of ozekibart’s application and ongoing trial updates shape Inhibrx Biosciences’ investment narrative.

Capitalize on the AI infrastructure…